Callos Bone Void Filler is indicated to the following indications:
1 . To fill bony voids or gaps of the skeletal system (i.e. extremities, spine, pelvis) not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.
2. To be used with autograft as a bone graft extender (i.e. extremities, and pelvis only).
Callos resorbs and is replaced by bone during the healing process.

Device Description

Callos Bone Void Filler is a moldable and biocompatible calcium phosphate bone void filler. The single-use Callos Kit contains the necessary components for mixing of the bone void filler. The Callos sterile kit contains: Calcium Phosphate Powder, Dilute Sodium Silicate Liquid, and a Mixing System (Mixing Bowl, Pestle and Spatula).

AI/ML Overview

The provided text is a 510(k) summary for the Callos® Bone Void Filler. This document describes the device, its intended use, and its substantial equivalence to predicate devices, but it does not contain information about acceptance criteria or a study that specifically proves the device meets particular numerical performance criteria.

Instead, the summary focuses on demonstrating substantial equivalence to previously approved devices based on:

Technological characteristics: Callos is composed of a calcium phosphate powder and a sodium silicate solution, which when mixed forms a paste that hardens into hydroxyapatite, similar to the mineral phase of native bone. Its function as a bone graft extender is similar to predicate devices.
Biocompatibility: In accordance with ISO 10993-1.
Sterilization validation: Compliant to ANSI/AAMI/ISO 11137-2.2006.
Physical/mechanical characteristics: Evaluated using setting tests (modified ASTM) and X-ray Diffraction (XRD) phase analysis, and compared with predicate devices.
Clinical use (for new indication): An "ewe study" (sheep study) demonstrated its use as an orthopedic bone graft extender.

Therefore, most of the specific questions about acceptance criteria, numerical performance, sample sizes, expert ground truth, adjudication, MRMC studies, or standalone algorithm performance cannot be answered from the provided text, as these concepts are typically associated with performance evaluations of diagnostic or AI-based devices, not material equivalence for a bone void filler as presented here.

However, I can extract the specific information that is present regarding the device and its evaluation methods.

1. Table of Acceptance Criteria and Reported Device Performance

As noted, the document does not present quantitative acceptance criteria or device performance in the manner typically seen for diagnostic devices (e.g., sensitivity, specificity, AUC). Instead, the "acceptance criteria" are implied by demonstrating substantial equivalence to predicate devices based on material properties, biocompatibility, and functional similarity.

Acceptance Criteria (Implied)	Reported Device Performance (as per 510(k) Summary)
Safety & Biocompatibility	In accordance with ISO 10993-1 ("Biological Evaluation of Medical Devices").
Sterility	Radiation sterilization validation compliant to ANSI/AAMI/ISO 11137-2.2006 ("Sterilization of Health Care Products - Radiation - Establishing the Sterilization Dose").
Physical/Mechanical Characteristics	Callos cement with added morselized bone was evaluated using setting tests (modified ASTM test method) and X-ray Diffraction (XRD) phase analysis. Compared with predicate devices. No specific numeric values or acceptance ranges are provided in this summary.
Material Composition & Hardened Form	Comprised of calcium phosphate salts, mixed with dilute sodium silicate solution to form a thick paste. Resulting hardened material is composed of hydroxyapatite, similar to the mineral phase of native bone tissue.
Resorption and Replacement by Bone	The device resorbs and is replaced by bone during the healing process. This is a functional characteristic described for Callos and its predicate devices.
Effectiveness as Bone Graft Extender (new indication)	"The ewe study demonstrated that Callos could also be used as an orthopedic bone graft extender." No specific quantitative results from this study are presented in this 510(k) summary. Substantially equivalent to predicate bone graft extenders (MasterGraft K082918, K082917; MBCP K051774) and bone void fillers (Callos K030554, K051123).

2. Sample Size Used for the Test Set and Data Provenance

Sample Size: Not specified in the provided summary.
Data Provenance: The "ewe study" is mentioned, indicating an animal (sheep) model in a prospective study design for the new indication as a bone graft extender. Other tests (biocompatibility, sterilization, physical/mechanical) are cited as having been performed previously for earlier Callos clearances (K030554 and K051123) and are standard laboratory evaluations. The location/country of origin is not specified.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of those Experts

Not applicable/provided. This type of detail is not required or typically included in a 510(k) summary for a bone void filler's substantial equivalence determination. The "ewe study" likely involved veterinary surgeons and pathologists, but specific numbers and qualifications are not listed.

4. Adjudication Method for the Test Set

Not applicable/provided. This is not relevant for the type of device and evaluation described.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

No MRMC study was done. This type of study is typically for evaluating the performance of diagnostic imaging devices or CAD systems, not for a bone void filler.

6. If a Standalone Study (Algorithm Only Without Human-in-the-Loop Performance) Was Done

Not applicable. This device is a medical implant, not an algorithm.

7. The Type of Ground Truth Used

For the "ewe study," the ground truth for evaluating bone graft extension would likely involve histopathology (analysis of tissue samples under a microscope to confirm bone formation, resorption of the material, integration with host bone) and potentially radiographic imaging over time. For the physical/mechanical tests, the "ground truth" is defined by the standardized test methods (e.g., modified ASTM) and the material characteristics of the predicate devices.

8. The Sample Size for the Training Set

Not applicable. This is not a machine learning or AI device that requires a training set. The "ewe study" could be considered a "test set" for the expanded indication.

9. How the Ground Truth for the Training Set Was Established

Not applicable. No training set is involved.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains a handwritten sequence of characters. The sequence starts with the letter 'K', followed by the number '1', and then two zeros '00'. After that, the numbers '986' are written. The entire sequence appears to be a combination of alphabetic and numeric characters, possibly representing a code or identifier.

Image /page/0/Picture/1 description: The image shows a logo with a stylized globe on the left and the words "Skeletal Kinetics" on the right. The globe is made up of intersecting lines, creating a grid-like pattern. The text is in a bold, sans-serif font, with "Skeletal" on the top line and "Kinetics" on the bottom line. The logo appears to be for a company or organization related to skeletal movement or biomechanics.

A COLSON ASSOCIATE

JUL 2 0 2010

510(k) Summary

General Information as required by 21 CFR 807.92 (a) (1)

Submitters Name/address:	Skeletal Kinetics® LLC10201 Bubb RoadCupertino, CA 95014, USA
--------------------------	-----------------------------------------------------------------------

Contact Person: Christine Kuo, Director, Regulatory Affairs and Quality Assurance
Fax: (408) 366-1077 Contact Numbers: Phone: (408) 350-5842,

June 25, 2010 Date Prepared:

Device Name as required by 21 CFR 807.92 (a) (2)

Trade Names:	Callos® Bone Void Filler (Callos),SKaffold™ Next Generation Bone Void Filler,OsteoVation® EX Bone Void Filler
Common Name:	Resorbable Calcium Salt Bone Void Filler
Classification:	21 CFR 888.3045
Product Code:	MOV

Predicate Devices as required by 21 CFR 807.92 (a) (3)

The subject device is substantially equivalent in safety and effectiveness to the following legally marketed devices (predicates):

MasterGraft® Resorbable Ceramic Granules of Medtronic (K082918) I.
II. MasterGraft® Resorbable Ceramic Granules of Medtronic (K082917)
III. MBCPTM of Biomatlante (K051774)
Callos® of Skeletal Kinetics (K030554 and K051123) IV.

{1}------------------------------------------------

Device Description as required by 21 CFR 807.92 (a) (4)

Intended Use as required by 21 CFR 807.92 (a) (5)

Callos is indicated to fill bony voids or gaps of the skeletal system (i.e. extremities, pelvis) not intrinsic to the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. Callos can be used with autograft as a bone graft extender. Callos resorbs and is replaced by bone during the healing process.

Summary of Technological Characteristics as required by 21 CFR 807.92 (a) (6)

Callos is comprised of two working components: a calcium phosphate powder and a sodium silicate solution. The basic design of Callos requires the end-user to mix the powder component with the liquid solution to create a paste-like substance to be used as a bone graft extender. The device resorbs and is replaced by bone during the healing process.

Summary of Non-clinical Tests as required by 21 CFR 807.92 (b) (1)

The biocompatibility of Callos is in accordance with the standard set forth in ISO 10993-1. Biological Evaluation of Medical Devices and the radiation sterilization validation of Callos is compliant to ANSI/AAMI/ISO 11137-2.2006, Sterilization of Health Care Products - Radiation - Establishing the Sterilization Dose. These tests were evaluated during Callos® K030554 and K051123 clearances.

Callos is a previously cleared and commercially marketed calcium phosphate bone void filler. The physical/mechanical characteristics of Callos cement with added morselized bone was evaluated using setting test (modified ASTM test method) and X-ray Diffraction (XRD) phase analysis and compared with predicate device.

Summary of Clinical Tests as required by 21 CFR 807.92 (b) (2)

Callos, an orthopedic bone void filler, is composed of calcium phosphate salts (tricalcium phosphate) that when mixed with a dilute sodium silicate solution form a thick paste. The resulting hardened material is composed of hydroxyapatite similar to the mineral phase of native bone tissue. There are no adverse metabolic breakdown products following implantation of hydroxyapatite, this material is the principal constituent of many approved orthopedic devices including Callos bone void filler.

The purpose of this 510(k) notification is to expand Callos' indications so that it may be used with autograft as a bone graft extender. The ewe study demonstrated that Callos could also be used as an orthopedic bone graft extender; Callos is substantially

{2}------------------------------------------------

equivalent to previously approved bone graft extenders predicate (I, II & III) and to bone void filler predicate (I, II, III, and IV) as described below:

Predicate device I (K082918), MasterGraft Resorbable Ceramic Granules of Medtronic is a bone void filler with a mixture of 60% hydroxyapatite and 40% βtricalcium phosphate formulation (may also be provided in a 15% hydroxyapatite and 85% ß-tricalcium phosphate formulation). Similar to Callos, it is a single use sterile osteoconductive implant and can be used with autograft as a bone graft extender.

Predicate device II (K082917), MasterGraft Resorbable Ceramic Granules of Medtronic is a bone void filler with a mixture of 60% hydroxyapatite and 40% ßtricalcium phosphate formulation (may also be provided in a 15% hydroxyapatite and 85% B-tricalcium phosphate formulation). Similar to Callos, it is a single use sterile osteoconductive implant to be used as a bone void filler or combined with autograft as bone graft extender to be use in maxillofacial region.

Predicate device III (K051774), MBCP of Biomatlante is a bone void filler with a mixture of 60% hydroxyapatite and 40% B-tricalcium phosphate. Similar to Callos, it is a single use sterile implant, and can be used with autograft as a bone graft extender.

Predicate device IV (K030554, K051123), Callos of Skeletal Kinetics, the same device as the subject device for this 510k notification, is a bone void filler as describe above.

Conclusion as required by 21 CFR 807.92 (3)

The summary above shows that Callos is substantially equivalent to the predicate devices and the tests demonstrate that the device is as safe, as effective, and performs as well as the legally market devices.

{3}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with three lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Skeletal Kinetics, LLC % Ms. Christine Kuo Director, Regulatory Affairs & Quality Assurance 10201 Bubb Road Cupertino, California 95014

JUL 2 0 2010

Re: K100986

Trade/Device Name: Callos® Bone Void Filler Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: II Product Code: MOV Dated: June 3, 2010 Received: June 4, 2010

Dear Ms. Kuo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).: You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register,

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{4}------------------------------------------------

Page 2 - Ms. Christine Kuo

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050,

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm far the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR, Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tolloffre are (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely vours.

Barbara Buehr

Mark N. Melkerso Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for Use Section 4:

K100986 510(K) Number (if Known):

Device Name:

Callos® Bone Void Filler

Indications for Use:

Callos Bone Void Filler is indicated to the following indications:

1 . To fill bony voids or gaps of the skeletal system (i.e. extremities, spine, pelvis) not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone.

To be used with autograft as a bone graft extender (i.e. extremities, and pelvis only).

Callos resorbs and is replaced by bone during the healing process.

X Prescription Use (Per 21 CFR 801 Subpart D)

Over-the-Counter Use (21CFR 801 Subpart C

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

AND/OR

Concurrence of CDRH, Office of Device Evaluation (ODE) (Divis Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number

Skeletal Kinetics LLC - Confidential

Page 10 of 42

Regulation Number and Section

§ 888.3045 Resorbable calcium salt bone void filler device.

(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.